CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 56 enrolled
Drug / intervention
Tamoxifen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02070692
NCT02070692Phase 4Completed
CompareCT.gov

Tamoxifen for the Treatment of Unfavorable Bleeding Patterns in Etonogestrel Contraceptive Implant Users

Oregon Health and Science University·interventional·Posted Feb 25, 2014·Updated Jul 2, 2017

In Brief

A Phase 4 clinical trial evaluating Tamoxifen and Placebo for Menstruation Disturbances. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenstruation Disturbances
CountriesUnited States
CollaboratorsSociety of Family Planning

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2014
Enrollment StartFeb 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.4 years ago

Interventions

Tamoxifendrug

7 day course of tamoxifen during an episode of irregular vaginal bleeding

Placebodrug

7 day course of placebo during an episode of irregular vaginal bleeding